8-K: PACS Group Reports Mixed Q2 2024 Results Amidst Revenue Growth and Increased Stock Compensation Costs

PACS Group announced a 29% year-over-year revenue increase for Q2 2024, but also reported a net loss due to a significant rise in stock-based compensation expenses.

Summary

• PACS Group reported a net loss of $10.9 million for the second quarter of 2024, primarily due to a $90.9 million increase in stock-based compensation expense related to restricted stock units granted during their April 2024 IPO.
• Despite the net loss, the company's consolidated revenue for the first six months of 2024 reached $1.9 billion, a 31% increase compared to the same period last year.
• Second-quarter revenue was $981.8 million, a 29% increase year-over-year and a 5% increase compared to the first quarter of 2024.
• Adjusted EBITDA for the first six months of 2024 was $188.2 million, and $99.7 million for the second quarter.
• Adjusted EBITDAR was $318.0 million for the first six months and $165.6 million for the second quarter.
• The company has increased its full-year 2024 revenue guidance to a range of $3.85 billion to $3.95 billion and adjusted EBITDA guidance to a range of $370 million to $380 million.
• Total facility occupancy was 91.0% in the second quarter of 2024, with ramping and mature facilities showing occupancy increases of 1.4% and 1.0%, respectively, compared to the same quarter last year.
• Average Medicare and Medicaid daily rates increased by 9.5% and 3.5%, respectively, in the second quarter of 2024 compared to the same quarter of the prior year.
• PACS added 2 operating facilities with 167 skilled nursing beds in the second quarter of 2024.
• The company added 3,947 operational beds over the twelve months ending June 30, 2024, leading to a 24.8% increase in patient days for the second quarter of 2024 compared to the same quarter of the prior year.
• PACS added 32 facilities and 12 real estate acquisitions during the 12 months ending June 30, 2024.
• Since the end of the second quarter, PACS has added another 28 facilities across four new states, bringing the total operated facilities to 248 and properties wholly owned or owned through JV partnerships to 87.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and increased guidance, but tempered by the net loss and significant stock-based compensation expense. The company is growing but has some challenges to overcome.

Positives

• PACS Group achieved a significant 29% year-over-year revenue increase in the second quarter of 2024.
• The company's total revenue for the first six months of 2024 increased by 31% compared to the same period last year.
• Occupancy rates remained strong at 91.0% across all facilities in the second quarter of 2024.
• The company increased its full-year revenue and adjusted EBITDA guidance.
• PACS added 32 facilities and 12 real estate acquisitions during the 12 months ending June 30, 2024.
• The company has expanded its operations to 248 facilities across 13 states.

Negatives

• PACS Group reported a net loss of $10.9 million for the second quarter of 2024.
• The net loss was primarily driven by a substantial $90.9 million increase in stock-based compensation expense.
• The skilled mix by revenue decreased from 58.0% to 51.2% year over year.
• The skilled mix by nursing patient days decreased from 34.7% to 29.2% year over year.

Risks

• The company's financial performance is subject to risks related to reimbursement from third-party payors.
• Changes in the acuity mix of patients and payor mix can impact financial results.
• Increased competition for skilled personnel, such as nurses, poses a risk.
• Regulatory changes in the healthcare industry could affect the company's operations.
• The company faces risks associated with litigation and reliance on information technology.
• There are risks associated with future facility or business acquisitions.
• The company is dependent on payments from third-party payors, including Medicare and Medicaid.
• The company is subject to various government and third-party payor reviews, audits, and investigations.

Future Outlook

PACS Group has increased its full-year 2024 revenue guidance to a range of $3.85 billion to $3.95 billion and adjusted EBITDA guidance to a range of $370 million to $380 million. The company continues to actively consider opportunities to acquire both performing and underperforming operations.

Management Comments

• Jason Murray, PACS's Chief Executive Officer, stated that the company's facilities continue to focus on clinical excellence and that he is pleased with the outcomes they are achieving.
• Jason Murray also noted that 165 of their facilities have a 4 or 5 star CMS Quality Measures rating, which is a key driver of revenue growth.
• Derick Apt, PACS's Chief Financial Officer, highlighted the strong occupancy across all facilities at 91.0% in the second quarter of 2024.

Industry Context

The announcement reflects the ongoing trends in the post-acute healthcare industry, including the importance of occupancy rates, reimbursement rates, and the impact of acquisitions on growth. The company's focus on clinical excellence and quality measures aligns with industry standards and regulatory requirements.

Comparison to Industry Standards

• The company's revenue growth of 29% year-over-year is strong compared to many other companies in the post-acute care sector, which often see growth in the single-digit or low double-digit range.
• The occupancy rate of 91.0% is generally considered good in the skilled nursing industry, although some top-performing facilities may achieve slightly higher rates.
• The increase in Medicare and Medicaid daily rates is in line with industry trends, as reimbursement rates are often adjusted annually.
• The company's focus on acquisitions and expansion is a common strategy in the industry, with many companies seeking to grow through both organic means and strategic purchases.
• The impact of stock-based compensation on net income is a common issue for companies, particularly after an IPO, and the $90.9 million expense is significant.

Stakeholder Impact

• Shareholders may be concerned about the net loss in Q2 2024, despite the strong revenue growth.
• Employees may be positively impacted by the company's growth and expansion.
• Customers (patients and residents) should benefit from the company's focus on clinical excellence and quality measures.
• Suppliers and creditors may see increased business opportunities due to the company's growth.

Next Steps

• The company will hold a conference call and webcast on August 12, 2024, to discuss the second quarter financial results.
• PACS will file its Quarterly Report on Form 10-Q for the period ended June 30, 2024, with the SEC.

Key Dates

Keywords

healthcare, post-acute care, skilled nursing, revenue, EBITDA, EBITDAR, occupancy, Medicare, Medicaid, acquisitions, facilities